Skip to main content
Delfa

← Trials/Trial dossier/NCT00751907

CAPP

CompletedPhase 2

Cerebral and Peripheral Perfusion Pilot Study

Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function

Asset

Atorvastatin

Listed sites

1

Recruiting sites

-

Enrollment

16

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Age 40-65•MRI contraindications excluded

Primary endpoint

•Regional cerebral blood flow (rCBF)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDIA0138
NihK23AG026752
NCT IDNCT00751907
Other grantPilot AwardWisconsin Comprehensive Memory Program Pilot Award

Timeline

Milestones

Study start2006-06 (month precision)
Primary completion2007-04actual (month precision)
Study completion2007-04actual (month precision)
Study first posted2008-09-12estimated
Last update posted2019-09-09actual

Assets

Drug assets

Atorvastatin

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Adult (ages 40-65) children of parent with documented Alzheimer's disease

Exclusion criteria

•Current use of cholesterol lowering medication
•History of liver disease
•History of adverse reaction to statin medications
•Elevated lab values (CK and creatinine)
•Use of medications that counteract with atorvastatin
•History of dementia
•Currently pregnant
•Use of large quantities of grapefruit juice (more than 1 quart/day)
•Current involvement in another investigational drug study
•Contraindications to MRI

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging
1
Other (unclassified)
1

Neuroimaging

1 endpoint
Primary/protocol endpoint

Change in regional cerebral blood flow (rCBF)

Time frame:Baseline and 4 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Change in Endothelial function

Time frame:Baseline and 4 months

change from baseline, improvement

Publications (6)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.